Didanosine

Didanosine
Clinical data
Trade names	Videx
Other names	2′,3′-dideoxyinosine
AHFS/Drugs.com	Monograph
MedlinePlus	a691006
Pregnancy; category	AU: B2; ;
Routes of; administration	By mouth
ATC code	J05AF02 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only); US: WARNINGRx-only;
Pharmacokinetic data
Bioavailability	30 to 54%
Protein binding	Less than 5%
Elimination half-life	1.5 hours
Excretion	Kidney
Identifiers
	IUPAC name 9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3H-purin-6(9H)-one;
CAS Number	69655-05-6 ;
PubChem CID	135398739;
IUPHAR/BPS	4833;
DrugBank	DB00900 ;
ChemSpider	45864 ;
UNII	K3GDH6OH08;
KEGG	D00296 ;
ChEBI	CHEBI:490877 ;
ChEMBL	ChEMBL1460 ;
NIAID ChemDB	000004;
CompTox Dashboard (EPA)	DTXSID6022927 ;
ECHA InfoCard	100.129.182
Chemical and physical data
Formula	C10H12N4O3
Molar mass	236.231 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C3/N=C\Nc1c3ncn1[C@@H]2O[C@@H](CC2)CO;
	InChI InChI=1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1 ; Key:BXZVVICBKDXVGW-NKWVEPMBSA-N ;
	(verify)

Didanosine (ddI, DDI), sold under the brand name Videx, is a medication used to treat HIV/AIDS.^[2] It is used in combination with other medications as part of highly active antiretroviral therapy (HAART). It is of the reverse-transcriptase inhibitor class.

Didanosine was first described in 1975 and approved for use in the United States in 1991.^[3]